The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
Blood Cell Transplant

A-Z Index  |  Questions?  |  Order Publications

  • Print this
  • Email this

Glossary for the U.S. Patient Survival Report

Cell Source 

Where the blood-forming cells used for transplant are collected from.

  • Bone marrow produces blood-forming cells for the body. The bone marrow for a transplant is collected from a donor's pelvic bone during a surgical procedure in a hospital.
  • Peripheral blood stem cells (PBSC) are found in the bloodstream. Normally, the bone marrow releases a small number of blood-forming cells into the bloodstream. A donor receives injections of a medication that increases the number of blood-forming cells in the blood. Then, the donor's blood is collected in a non-surgical procedure done in an outpatient clinic.
  • Umbilical cord blood contains a large number of blood-forming cells. Cord blood is collected in a hospital after a baby is born.

Disease Status 

A measure of how the disease responded to treatment before the patient received a bone marrow or umbilical cord blood transplant. The disease status can help predict the likelihood of a better or worse survival outcome after transplantation.

In these reports, disease status is included only for leukemias and lymphomas.

Leukemia Disease Statuses

For chronic myelogenous leukemia (CML):

  • 1st remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • 2nd remission—The disease recurred after responding well to initial treatment (that is, the disease recurred after achieving a clinical remission). After further treatment, there is no clinical evidence of leukemia.
  • Not in remission—This includes the following:
    • 1st chronic phase—The disease responded well to treatment. There is still some clinical evidence of leukemia.
    • 2nd chronic phase—The disease recurred after responding well to initial treatment (that is, the disease achieved clinical remission, and then it recurred).
    • Blast phase—The disease is not responding to treatment.
    • Unknown—The disease status was not available.

For acute myleogenous leukemia (AML) or acute lymphoblastic leukemia (ALL):

  • 1st remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • 2nd remission—The disease recurred after responding well to initial treatment. After further treatment, there is no clinical evidence of leukemia.
  • Not in remission—The disease is not responding to treatment.
  • Unknown—The disease status was not available.

Lymphoma Disease Statuses

  • In remission—The disease responded well to treatment. There is no clinical evidence of lymphoma.
  • Not in remission—The disease is not responding to treatment. There is still some evidence of lymphoma.
  • Unknown—The disease status was not available.

Donor Type 

Biological relationship between the patient and the donor who provided the blood-forming cells.

  • Autologous—The patient's own cells were collected.
  • Allogeneic—A volunteer donated bone marrow, peripheral blood, or an umbilical cord blood unit. These cells match the patient’s human leukocyte antigen (HLA) type. Specific allogeneic types include:
    • HLA-matched sibling—The brother or sister who donated cells is the patient's biological sibling.
    • Related donor—The family member who donated cells is related biologically to the patient and is not included in the HLA-matched sibling category.
    • Unrelated—The person who donated cells is not related biologically to the patient.

Human Leukocyte Antigen (HLA)

Proteins on cells that make each person's tissue unique.

HLA typing is used to match patients and donors for a bone marrow or umbilical cord blood transplant. (A person's HLA type is identified by testing a blood sample or swab of cheek cells.)

95% Confidence Interval 

A range of numbers that represents the statistical certainty of the survival probability estimate, based on the data reported.

For example, a 95% confidence interval of 65 - 75% means there is 95% certainty that the survival probability estimate is between 65% and 75%.

Number of Patients Evaluated 

Number of patients for whom medical information was analyzed at 100 days after their bone marrow or umbilical cord blood transplant and was voluntarily reported to the Center for International Blood and Marrow Transplant Research® (CIBMTR).

Patient Age 

Age of a patient at the time of a bone marrow or umbilical cord blood transplant. These reports provide the age in 10-year intervals.

“Unknown” means the age was not reported.

Patient Gender 

The sex of a patient: male or female.

“Unknown” means the gender was not reported.

Patient Race 

Race or ethnicity of a patient. These reports have only two categories:

  • White, for Caucasian (non-Hispanic)
  • Non-white, for all other races and ethnicities

Survival Probability Estimate 

The best estimate of the chance that a person will be alive at a specified time after transplant. This estimate is based on the data reported. View an example.